Beyond the Molecule: Getting Psychedelic Therapy Right

Lest week’s announcement that the federal government will accelerate research into psychedelic therapies marks a turning point over 40 years in the making. 

This decision offers a reopening of a field long stunted: decades of research lost to a culture of fear and the Controlled Substances Act of 1970..

If this next chapter is going to succeed, we have to resist a familiar impulse: treating these compounds as drugs alone, rather than as part of a broader therapeutic process.

One of the most important precedents for this comes from Rick Doblin and the team at the Multidisciplinary Association for Psychedelic Studies (MAPS). When they pursued FDA approval for MDMA, they did not frame it as a standalone drug. They argued for MDMA-assisted therapy, a model in which the compound is inseparable from the psychological support that surrounds it.

That decision has real implications for regulators today. Approval pathways, clinician training, and reimbursement models will shape whether these treatments are delivered as integrated therapies, or reduced to brief, drug-centered encounters.

It also challenges an outdated model of mental illness that reduces conditions like depression to chemical imbalances. Emerging research, including Gül Dölen’s work on critical periods, suggests something more complex: these treatments may not simply alter chemistry, they may reopen the brain to new learning.

The recent history of ketamine offers a cautionary example. Introduced into mental health care as a fast-acting antidepressant, it was often framed as a next-generation SSRI.

The result has been a model in which patients receive infusions or prescriptions without sufficient therapeutic support, then return for ongoing treatment as symptoms reemerge. For some, this approach is lifesaving, particularly in acute crises. But for many, its effects are temporary. Without attention to the psychological and social conditions shaping a person’s life, relief fades, requiring repeated dosing and, in some cases, leading to dependency.

And this is where the conversation about psychedelics often goes wrong.

Psychedelics themselves are not inherently healing, insightful, or even beneficial. They are better understood as amplifiers: of context, of expectation, of psychological material that may be constructive or destabilizing. Under the right conditions, they can open space for new learning and emotional processing. Under the wrong ones, they can reinforce fear, confusion, or trauma.

Set, setting, and support are not secondary considerations; they are the intervention. To treat these compounds as if their effects are uniform or self-directing is to misunderstand them entirely and to risk causing harm in the very systems meant to deliver care. Haven’t we done enough of that?

We must resist presenting psychedelics as magic pills. Their potential lies in how they are used: facilitated in an environment of great safety, with skilled guidance, and integration processes that support genuine transformation.

If we get this right, these treatments could do more than alleviate symptoms. They could help create lasting relief from extreme suffering.

But that outcome isn’t guaranteed.

The question is not whether these therapies work. It’s whether we’re willing to build the systems required for them to work.

I feel tremendous hope that psychedelic-assisted care can play a role in dismantling outdated models of mental healthcare that urgently need change. And we must proceed with great care

Yours in care,
Erika